<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504501</url>
  </required_header>
  <id_info>
    <org_study_id>SYN-1748-MAL-0030-I</org_study_id>
    <secondary_id>2016-005022-10</secondary_id>
    <nct_id>NCT03504501</nct_id>
  </id_info>
  <brief_title>Synaptic Plasticity and Cognitive Function in RASopathies</brief_title>
  <acronym>SynCoRAS</acronym>
  <official_title>Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is targeting cognitive impairment, one of the main health problems of patients
      with RAS pathway disorders. The aim of this study is to translate findings of animal studies
      to humans. This has been done by the applicants successfully for Lovastatin in Nf1. This
      result will be transferred to patients with Noonan Syndrome. lamotrigine is most likely a
      more effective and promising substance improving synaptic plasticity and consecutive
      cognitive function. It is expected that both substances are improving synaptic plasticity as
      well as alertness and changes in alertness may be a precondition for improvement of
      cognition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Monocenter, randomized, double-blind, parallel-group, placebo controlled, cross-over design with a series of three experiments (Noonan Syndrome: 2 experiments; Neurofibromatosis type 1 1 experiment) and n=14 participants per experiments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term potentiation (LTP)-like plasticity measured with transcranial magnetic stimulation (TMS)</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in peak-to-peak amplitudes of motor evoked potentials (MEP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between the neuropsychological testing of attention (Test of attentional performance) after placebo and after medication (LTG and LOV)</measure>
    <time_frame>12 months</time_frame>
    <description>Response time (seconds) for alertness, visual scanning, Go/no Go, Incompatibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in short interval cortical inhibition (SICI) after placebo and after medication (LTG and LOV)</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in SICI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of safety: EMG recording during TMS evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Safety</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Impaired Synaptic Plasticity</condition>
  <condition>Impaired Cognition</condition>
  <arm_group>
    <arm_group_label>Exp. I: Noonan Syndrome - Lovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exp. II: Noonan Syndrome - Lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exp. III: Neurofibromatosis Type 1 - Lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <description>oral application prior to transcranial magnetic stimulation intervention</description>
    <arm_group_label>Exp. I: Noonan Syndrome - Lovastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>oral application prior to transcranial magnetic stimulation intervention</description>
    <arm_group_label>Exp. II: Noonan Syndrome - Lamotrigine</arm_group_label>
    <arm_group_label>Exp. III: Neurofibromatosis Type 1 - Lamotrigine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: NS, Group 2: NF1 (both genetically assured)

          -  Age &gt;18 years

          -  Signed informed consent.

          -  Persons who are capable to give their consent and understand the aim and rationale of
             the study. In case of doubts, an independent medical practitioner will evaluate the
             capacity to consent.

          -  Male participants and female participants who are not capable of bearing children or
             who use a method of contraception that is medically approved by the health authority
             of the respective country.

        Exclusion Criteria:

          -  Epilepsy

          -  Medication with known CNS effects

          -  Severe mental retardation

          -  Side effects during previous medication with and contraindications to LTG and/or LOV
             and/or TMS

          -  Psychiatric diseases

          -  Previous history of allergic reactions with LTG and LOV medications

          -  Potentially unreliable patients

          -  Patients who are not suitable for the study in the opinion of the investigator

          -  Pregnancy (incl. positive urine pregnancy test)

          -  Persons who are incapable of giving consent or do not understand the aim or rationale
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Volker Mall, Prof.</last_name>
    <phone>+49 (0)89 71009-233</phone>
    <email>volker.mall@kbo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikolai Jung, Dr.</last_name>
    <phone>+49 (0)89 71009-236</phone>
    <email>nikolai.jung@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Technical University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Mall, Prof.</last_name>
      <phone>+49 (0)89 71009-233</phone>
      <email>volker.mall@kbo.de</email>
    </contact>
    <contact_backup>
      <last_name>Nikolai Jung, Dr.</last_name>
      <phone>+49 (0)89 71009-236</phone>
      <email>nikolai.jung@tum.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mainberger F, Jung NH, Zenker M, Wahlländer U, Freudenberg L, Langer S, Berweck S, Winkler T, Straube A, Heinen F, Granström S, Mautner VF, Lidzba K, Mall V. Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. BMC Neurol. 2013 Oct 2;13:131. doi: 10.1186/1471-2377-13-131.</citation>
    <PMID>24088225</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RASopathies, neurofibromatosis type 1, noonan syndrome, synaptic plasticity, transcranial magnetic stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

